Skip to content

Feasibility Study of Preimplantation Genetic Diagnosis for Single-gene Disorders

Feasibility Study of Preimplantation Genetic Diagnosis for Single-gene Disorders by Using Nextgeneration Sequencing

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02502214
Enrollment
30
Registered
2015-07-20
Start date
2015-11-12
Completion date
2017-09-30
Last updated
2017-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preimplantation Diagnosis

Keywords

Preimplantation Genetic Diagnosis, PGD, Next-Generation Sequencing, NGS, Single-Gene disorders, Cystic Fibrosis, CFTR, Single-cell analysis, PCR, SNP, Whole Genome Amplification

Brief summary

Preimplantation Genetic Diagnosis (PGD) for monogenic diseases is usually performed by multiplex PCR combining polymorphic microsatellites familial analysis and, where possible, couple-specific mutation detection. Single-cell multiplex PCR developments are costly and time-consuming. We propose to test and clinically validate a targeted next-generation sequencing approach for the PGD for cystic fibrosis. This technique would allow a PGD for probably almost every couple asking for it in our centre, without a previous couple-specific development (but only a preliminary familial analysis). It will be based on haplotyping using a large number of SNPs and mutation detection. A clinical validation will be performed by reanalysing non-transferable embryos obtained after PGD for cystic fibrosis, with couple's informed consent. Concordance of the results between PGD and reanalysis by NGS will be achieved and if validated, this technique may be applied to future PGD for cystic fibrosis in our centre. The same technique may then be applied for other PGD indications for which a set-up is often needed.

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age\> or = 18 years * Couples at risk of transmitting cystic fibrosis * asking for a PGD in Strasbourg * DNA samples available at the laboratory for: * The couple * A related with CFTR status known * Having signed an informed consent

Exclusion criteria

* Inability to give informed consent (understanding difficulties...)

Design outcomes

Primary

MeasureTime frame
Monogenic diseasesfor the duration of hospital stay, up to 1 year

Countries

France

Contacts

Primary ContactCéline Moutou, MD
celine.moutou@chru-strasbourg.fr03.69.55.34.21
Backup ContactEmmanuelle KIEFFER, PhD
emmanuelle.kieffer@chru-strasbourg.fr03.69.55.34.21

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026